Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 8/20 | 0.65 |
| ▸ | POLB | P06746 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 7/20 | 0.57 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | CASP3 | P42574 | 1/20 | 0.52 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.52 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.52 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | NAMPT | P43490 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6817067 | 0.88 | NAMPT (0.61) | NPC1POLBMEN1KMT2AMAPT | |
| SCHEMBL28262243 | 0.83 | ANO1 (0.52) | NPC1POLBMEN1KMT2AMAPT | |
| SCHEMBL19512747 | 0.82 | MAP4K4 (0.46) | NPC1POLBMEN1KMT2AMAPT | |
| SCHEMBL8336826 | 0.82 | PABPC1 (0.51) | NPC1POLBMEN1KMT2AMAPT | |
| SCHEMBL240482 | 0.82 | TRPV1 (0.61) | NPC1POLBMAPTRAB9ANOTUM | |
| SCHEMBL8115168 | 0.82 | NPC1 (0.70) | NPC1POLBMEN1KMT2AMAPT | |
| SCHEMBL3403454 | 0.80 | KAT6A (0.60) | NPC1POLBMEN1KMT2AMAPT | |
| SCHEMBL30216106 | 0.80 | KAT6A (0.60) | NPC1POLBMEN1KMT2AMAPT | |
| SCHEMBL1538297 | 0.80 | NPC1 (0.77) | NPC1POLBMEN1KMT2AMAPT | |
| SCHEMBL29728201 | 0.80 | NPC1 (0.77) | NPC1POLBMEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2661431-B1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2018-07-11 | — | — | EP | disclosed |
| EP-2661431-B1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2018-07-11 | — | — | EP | disclosed |
| US-9701637-B2 | Tau imaging probe | GE HEALTHCARE LIMITED (GB) | 2017-07-11 | — | — | US | disclosed |
| US-9452985-B2 | Tau imaging probe | GE HEALTHCARE LIMITED (GB) | 2016-09-27 | — | — | US | disclosed |
| US-20160271278-A1 | TAU IMAGING PROBE | GE HEALTHCARE LTD (GB) | 2016-09-22 | — | — | US | disclosed |
| US-9249101-B2 | Tau imaging probe | CLINO LTD. (JP) | 2016-02-02 | — | — | US | disclosed |
| US-20160008494-A1 | TAU IMAGING PROBE | GE HEALTHCARE LIMITED (GB) | 2016-01-14 | — | — | US | disclosed |
| US-9073902-B2 | Substituted quinoxaline carboxylic acid compounds for the inhibition of PASK | BIOENERGENIX, LLC (US) | 2015-07-07 | — | — | US | disclosed |
| US-9073902-B2 | Substituted quinoxaline carboxylic acid compounds for the inhibition of PASK | BIOENERGENIX, LLC (US) | 2015-07-07 | — | — | US | disclosed |
| US-9073902-B2 | Substituted quinoxaline carboxylic acid compounds for the inhibition of PASK | BIOENERGENIX, LLC (US) | 2015-07-07 | — | — | US | disclosed |
| US-20120220589-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2012-08-30 | — | — | US | disclosed |
| US-20120220589-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2012-08-30 | — | — | US | disclosed |
| US-20120220589-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2012-08-30 | — | — | US | disclosed |
| WO-2012094462-A2 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | BIOENERGENIX (US) | 2012-07-12 | — | — | WO | disclosed |
| WO-2012057312-A1 | TAU IMAGING PROBE | クリノ株式会社 (JP) | 2012-05-03 | — | — | WO | disclosed |
| WO-2012029763-A1 | DIAMINE, POLYIMIDE PRECURSOR, POLYIMIDE, LIQUID-CRYSTAL ALIGNMENT MATERIAL, LIQUID-CRYSTAL ALIGNMENT FILM, AND LIQUID-CRYSTAL DISPLAY ELEMENT | 日産化学工業株式会社 (JP) | 2012-03-08 | — | — | WO | disclosed |
| US-6949543-B2 | Amide derivative | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-27 | — | — | US | disclosed |
| EP-1340750-B1 | AMIDE DERIVATIVES | YAMANOUCHI PHARMA CO LTD (JP) | 2005-08-17 | — | — | EP | disclosed |
| US-20040034232-A1 | Amide derivative | ASTELLAS PHARMA INC. (JP) | 2004-02-19 | — | — | US | disclosed |
| EP-1340750-A1 | AMIDE DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2003-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220589-A1 | HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK | PASK, PDXK, PANK2 | NPC1 3570/4885POLB 1468/4885MEN1 3040/4885 |
| US-20160008494-A1 | TAU IMAGING PROBE | MAPT, APP, APBA1 | NPC1 394/4885POLB 4142/4885MEN1 442/4885 |
| US-20160271278-A1 | TAU IMAGING PROBE | MAPT, APP, APBA1 | NPC1 394/4885POLB 4142/4885MEN1 442/4885 |
| US-20040034232-A1 | Amide derivative | HDAC2, ZC3HAV1, HDAC4 | NPC1 3690/4885POLB 3218/4885MEN1 4073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.